Boston Scientific Corporation (BSX) : The money flow analysis of Boston Scientific Corporation (BSX) indicates a $0.71 million of outflow was on downticks, whereas, the investors on Monday gobbled up stocks worth $2.07 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 2.91 and so was the total money flow at $1.36 million. The bulls lapped up $1.55 million worth of block trades on upticks. The money flow was $1.55 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Boston Scientific Corporation (BSX), pushing it down by -0.13% for the day. The stock slid $0.03 and traded at $23.55 during the day. Nonetheless, the stock is -1.46% over the previous weeks close.
Boston Scientific Corporation is up 21.11% in the last 3-month period. Year-to-Date the stock performance stands at 27.87%. Boston Scientific Corporation has dropped 0.8% in the last five trading days, however, the shares have posted positive gains of 3.29% in the last 4 weeks. In a related news,The officer (EVP, GC & Chief Admin Officer) of Boston Scientific Corp, Pratt Timothy A. sold 24,000 shares at $23.39 on July 1, 2016. The Insider selling transaction had a total value worth of $561,360. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation (NYSE:BSX): The stock was completely flat for the day, closing at $23.58 on Monday. The flat closing masks the intraday volatility in the stock. After opening at $23.66, the stock touched an intraday high of $23.71 and a low of $23.51. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $23.58. The total trading volume on Monday was 5,210,764.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.